- Home
- KNSA vs GOF Comparison
KNSA vs GOF Comparison
Compare KNSA & GOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSA | GOF |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNSA | GOF |
|---|---|---|
| Price | $38.58 | $13.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $51.33 | N/A |
| AVG Volume (30 Days) | 510.1K | ★ 789.2K |
| Earning Date | 02-24-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 15.42% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $597,973,000.00 | N/A |
| Revenue This Year | $61.60 | N/A |
| Revenue Next Year | $29.82 | N/A |
| P/E Ratio | $88.08 | ★ N/A |
| Revenue Growth | ★ 55.68 | N/A |
| 52 Week Low | $17.82 | $10.96 |
| 52 Week High | $44.42 | $16.76 |
Technical Indicators
Market Signals| Indicator | KNSA | GOF |
|---|---|---|
| Relative Strength Index (RSI) | 36.23 | 62.08 |
| Support Level | $39.16 | $12.68 |
| Resistance Level | $43.00 | $13.09 |
| Average True Range (ATR) | 1.70 | 0.20 |
| MACD | -0.29 | 0.06 |
| Stochastic Oscillator | 6.41 | 91.29 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.